The dissemination of medical information online in real time has forever changed the relationship between today's physician and patient. The idea that accurate and meaningful information can only flow in one direction is now extinct.
How can physicians take advantage of social media (SM)-in the form of online forums, microblogs (eg, Twitter), video, blogs, social networks, and podcasts1-as an opportunity to engage with patients and improve their care?
Here to discuss is Dr Farris Timimi, Assistant Professor of Medicine at the Mayo Clinic and Medical Director of the Mayo Clinic Center for Social Media, in Rochester, Minn. Dr Timimi can be found on Twitter at @FarrisTimimi.
Social Media in Medicine
Take home points
• SM is an opportunity for physicians to change community outcomes and improve patient care
• Because the 3 most common online activities include internet search, e-mail, and searching for health care information, physicians are obligated to put reliable health care information in the path of the patient
• SM is a logical extension of clinical practice, research, and education
• Content curation and content creation have “profound value” to patients and caregiver, so it is incumbent upon physicians to develop and review their organizational SM policy guide1
Reference
1. Timimi FK. Medicine, morality and health care. BMC Med. 2012;10:83.
Social Media and Medicine: A Winning Combination
Dr Farris Timimi, Assistant Professor of Medicine at the Mayo Clinic and Medical Director of the Mayo Clinic Center for Social Media, discusses the potential of social media to change the landscape of clinical practice.
The dissemination of medical information online in real time has forever changed the relationship between today's physician and patient. The idea that accurate and meaningful information can only flow in one direction is now extinct.
How can physicians take advantage of social media (SM)-in the form of online forums, microblogs (eg, Twitter), video, blogs, social networks, and podcasts1-as an opportunity to engage with patients and improve their care?
Here to discuss is Dr Farris Timimi, Assistant Professor of Medicine at the Mayo Clinic and Medical Director of the Mayo Clinic Center for Social Media, in Rochester, Minn. Dr Timimi can be found on Twitter at @FarrisTimimi.
Social Media in Medicine
Take home points
• SM is an opportunity for physicians to change community outcomes and improve patient care
• Because the 3 most common online activities include internet search, e-mail, and searching for health care information, physicians are obligated to put reliable health care information in the path of the patient
• SM is a logical extension of clinical practice, research, and education
• Content curation and content creation have “profound value” to patients and caregiver, so it is incumbent upon physicians to develop and review their organizational SM policy guide1
Reference
1. Timimi FK. Medicine, morality and health care. BMC Med. 2012;10:83.
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.
Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair
Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.
Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis
AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.
Lebrikizumab Improves Patient-Reported Outcomes in Atopic Dermatitis for Patients Previously Treated with Dupilumab
The proportion of participants with poor response to dupilumab who achieved a PNRS improvement of 3 points or greater was 72.9% at week 16 and 77.5% at week 24.
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.
Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair
Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.
Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis
AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.
Lebrikizumab Improves Patient-Reported Outcomes in Atopic Dermatitis for Patients Previously Treated with Dupilumab
The proportion of participants with poor response to dupilumab who achieved a PNRS improvement of 3 points or greater was 72.9% at week 16 and 77.5% at week 24.